First Horizon Advisors, Inc. Vericel Corp Transaction History

First Horizon Advisors, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	SELL	$22.62 - $32.54 $3,619 - $5,206	-160 Closed	0 $0
Q2 2022 Aug 02, 2022	BUY	$22.88 - $39.45 $3,660 - $6,312	160 New	160 $4,000
Q4 2021 Feb 09, 2022	SELL	$35.2 - $52.6 $2,886 - $4,313	-82 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$46.35 - $59.75 $1,714 - $2,210	37 Added 82.22%	82 $4,000
Q3 2021 Nov 09, 2021	BUY	$46.35 - $59.75 $2,085 - $2,688	45 New	45 $2,000
Q1 2020 May 05, 2020	SELL	$7.25 - $19.22 $2,581 - $6,842	-356 Closed	0 $0
Q3 2019 Oct 23, 2019	BUY	$14.93 - $19.83 $5,315 - $7,059	356 New	356 $5,000

275

48.4M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.76B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on First Horizon Advisors, Inc. with notifications on news.